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A ROAD LESS TRAVELLED BY
"Two roads diverged in a wood, and I
took the one less travelled by,
And that has made all the difference."
Robert Frost (1874-1963)
In his book "Genome" Matt Ridley has said
"scientistsarenotinterestedinknowledge-only
ignorance and mysteries". My review will
therefore be unlikely to inform but rather to
bewilder!
My title is taken from Robert Frost's famous
poem and indeed I believe I have explored not
one but many rarely frequented avenues of
research in neuropsychopharmacology. Looking
backover30years, however, IthinkIcandiscern
a pattern of sorts which, I trust, I will be able to
persuade you to see as well. The total "journey"
is summarised in Table 1.
The story started with an aspect ofmy MD thesis
("Some aspects ofthe role ofcortisol in relation
toaffectivedisorder", 1971) inwhichIexamined
apossiblelinkbetweenelevatedcortisol(aknown
finding in depressive illness) and decreases in
brain serotonin (5HT). The idea was that raised
cortisol levels by inducing a liver enzyme,
tryptophan oxygenase, diverted circulating
tryptophan down the kynurenine pathway, so
reducing the amount oftryptophan available for
5HT synthesis in the brain, thus leading to
depression.' Since the rate limiting enzyme in
5HTsynthesis wastryptophanhydroxylaseIfirst
demonstrated that there was a reduced level of
this enzyme in the brain of rats which had been
injected with cortisol in comparison with those
which had not: an effect which wasprevented by
the co-administration of allopurinol (which
inhibits tryptophan oxygenase intheliver). I was
further able to show, in a longitudinal study in
TABLE 1
A road less travelled by: Highways and Byways
1969-87 Neuroendocrinology (Transcortin and
dexamethasone suppression in depression;
cortisol and tryptophan hydroxylase in rat
brain).
1975-82 Pharmacovigilance (inter and intra-regional
differences in psychotropic drug
prescribing).
1979-89 Viruses and mental illness (Serum and CSF
viral antibodies in psychiatric patients).
1979-2001 Biological Psychiatry (CSF amines,
peripheraladrenergicreceptors,neurological
soft signs, CT scans, eye movements).
1980-97 Drug trials of new/novel antipsychotics
(propranolol, ondansetron, remoxipride,
quetiapine, sertindole, zotepine,ziprasidone,
M100907).
1982-95 Pharmacokinetics of antipsychotic drugs in
patients(haloperidol,remoxipride,zotepine).
1985-2001 Pharmacodynamics of antipsychotic drugs
in healthy volunteers (eye movements,
"McCollough Effect', EEG, psychomotor
function,cognition,auditoryandvisuallatent
inhibition, pre-pulse inhibition, heart rate
variability).
1993- *Neuropharmacology (animal studies using
latent inhibition, in vivo microdialysis,
quantitative autoradiography).
2000- *Functional neuroimaging (SPECT studies
ofacutetryptophan depletion inpatients and
healthy volunteers).
*Combined programme: "The role of the pre-frontal
serotonin system in cognition ".
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which rats were sacrificed every two hours for a
twenty fourhourperiod, that this effect could be
explained by a phase shift in the activity of
tryptophan hydroxylase. This was particularly
interestingsincetheabnormalityincortisollevels
reported in mood disorders was an exaggeration
ofthe normal diurnal variation oraphase shift in
this circadian rhythm.
At this point I had to leave laboratory research
butwas eventually veryfortunate inbeing ableto
combine my interest in biochemistry and
pharmacology with clinical psychiatry, by being
appointed jointly to the Department of
Therapeutics and Pharmacology at Queen's
University, Belfast (perhaps the only
pharmacology department in the country with its
own psychiatrist!) and a local general adult
psychiatrichospital(HolywellHospital,Antrim).
Building on the earlier work ofOwen Wade and
Peter Elmes in that department I took an interest
in monitoring the use ofpsychiatric drugs in the
community from GP prescribing data. It was
clear, and the cause of some alarm at the time,
that this was rising, particularly the use of
benzodiazepines and antidepressants. This was
in the early 1970s at the peak ofour civil unrest,
and there were many newspaper headlines
suggesting that our increased use of these drugs
was aninappropriate response tothetroubles and
wasproducinga"tranquillisedprovince". Careful
analysis ofour data showed, however, that these
trends continued long after the worst of our
troubles; were similar in England and other
Western European countries; and could just as
readily be explained by the increase in the
availability of new compounds.2 Indeed the rise
in antidepressant prescribing continues and has
now exceeded that ofbenzodiazepines. We now
believe much depressive illness was previously
being unrecognised and is now more often
successfully treatedbyfamilypractitioners inthe
community, rather than as a specialist disorder
requiring psychiatric in-patient treatment.
Nevertheless, I wasprimarily concerned withthe
biological substrates of psychiatric illness and
began a series ofstudies on the neurotransmitter
metabolites found in cerebral spinal fluid (CSF)
of patients with psychotic disorders. Lumbar
puncture studies would now be regarded as
unjustifiably invasive but this was the best we
could do before the advent of in vivo
neuroimaging.TogetherwithDrStephenCooper,
wewereabletoshowthatECT(Electroconvulsive
Therapy) and a standard antipsychotic drug,
haloperidol, werebothassociatedwithatransient
increase of the dopamine metabolite (HVA) in
the CSFofschizophrenic patients.3 ECT, despite
its detractors, is still the "gold standard" by
which other treatments for severe psychotic
depressionhavetobemeasured.Itisalsoeffective,
albeit temporarily, in otherwise treatment-
refractory schizophrenia. We had thus
demonstrated that ECT was having an
antipsychotic action through a similar effect on
thedopaminepathwaysasstandardantipsychotic
drugs. Aninteresting sequel tothese CSF studies
was a follow up carried out on the subsequent
course of those schizophrenic patients who had
had lumbar punctures eleven years previously.4
We found that ten of the original thirty patients
had subsequently madeasuicideattemptandthat
these had had significantly lower CSF levels of
the 5HT metabolite, 5-HIAA, at the time of the
original illness. This was consistent with the
previous depression literature, but seemed to
point to a link with the depressed mood itself
rather than impulsivity, since there was no
association between low CSF 5-HIAA and more
violent suicide attempts orotherforms ofviolent
behaviour.
We were driven by two convictions: (1) the need
to find an objective, measurable correlate of
psychotic illness and (2) that new antipsychotic
drugs could be found which would be both more
effective and better tolerated than existing
treatments.
We did indeed confirm that neurological "soft
signs" were present in schizophrenic patients
and, in collaboration with John Waddington,
correlated the cognitive impairment in these
patients with increasedlateral ventricularsize on
CT(ComputerisedTomography) scans.5Wealso
replicated by objective measurement, an
observation which had first been made in 1908,6
that these patients had abnormal eye movements
when carrying out simple "smooth pursuit"7 or
"antisaccade"8 tasks. We measured both smooth
pursuit tracking and saccadic eye movements
using a simple electro-oculographic (EOG)
system. Saccades arerapideyemovements which
occur when visual attention is switched between
objects of regard and are the fastest movements
of which the body is capable, reaching peak
velocities ofup to 600°/sec. The speed ofthese is
unchanged in schizophrenia but when the task is
to inhibit the tracking and instead to look in an
C The Ulster Medical Society, 2003.
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equal and opposite direction (the antisaccade
paradigm), schizophrenic patients make many
more errors. We were not, however, able to
distinguish between treatment responsive and
treatment refractory patients using this method.
Our quest for new and bettertreatments led us to
trynewcompounds,ornewusesofoldcompounds
(propranolol) and also to explore the possibility
thatpharmacokineticdifferencesbetweenpatients
led to their resistance to treatment. The
propranolol story demonstrated that its apparent
efficacy in schizophreniawas dueto apositive or
beneficial pharmacokinetic interaction whereby
the addition of propanolol, by inhibiting the
metabolism of the adjunctive antipsychotic,
increased the plasma levels of those drugs.9' 10
This encouraged us to embark on a somewhat
"heroic" study ofvery high levels ofhaloperidol
in an attempt to improve treatment refractory
schizophrenic patients - perhaps this is where
the toxicology comes in!. There was, however, a
negative result in that, although we achieved
somewhathazardous serum haloperidol levels of
upto 100ng/ml,therewasnoadditionalresponse
withlevels above 20ng/ml."I Thishasrepeatedly
been found with subsequent studies which show
thatthere is noadditionalresponse tohaloperidol
in doses above 20 mg per day.
The other drug studies carried out at Holywell
Hospital over this period of time are listed in
Table 2. Clozapine, the first "atypical"
antipsychotic which had been shown to be
effectiveinotherwisetreatment-resistantpatients
and to have a low incidence of adverse
extrapyramidal side-effects, but which also
carried a substantial risk of potentially fatal
agranulocytosis, was re-introduced in the United
Kingdom under limited licence procedures in
1990. We startedusing itinFebruary ofthatyear
and published the first series of24 patients to be
given clozapine in Ireland.'2 71% of these
previously, verydisturbedandtreatment-resistant
patientsimproved, onethirdmarkedly.However,
because of the risks with this drug a range of
"new atypicals" were being developed and we
participated in the early trials of a number of
these. An example is the remoxipride study.
Remoxipride is a selective D2 antagonist which
was subsequently withdrawn due to aplastic
anaemia. Crucial to its development was a
multicentrestudywhichwecarriedoutinNorthern
Ireland, which proved to be the only placebo
controlled trial to be done with this drug. We
demonstrated that when chronic schizophrenic
inpatients were randomised to remoxipride or
placebotherelapseratewassignificantlyreduced
intheremoxipridegroup.13Thisstudywasdeemed
tobeethical atthetime sincethepatients hadhad
aminimalresponseto standardtreatmentandhad
shown no signs ofrelapse during a previous one
month placebo "wash out" phase. These studies
underline the greatchangethathas comeaboutin
the organisation of drug trials within the last
twenty-five years. It is even more remarkable to
read Heinz Lehmann's account of the first trial
with chlorpromazine about fifty years ago as
recorded by David Healy in his book on "The
Psychopharmacologists" (1996).
"So the next morning, which was a Monday, the
first residentImetwas DrHanrahan andIasked
him 'Doyou want to startsome research with me
on a new drug?' andhe said 'yes'. So we didit ...
We decidedwe wouldtry itouton about 70or 75
patients. Nowadays, ofcourse, this would take
years but in those days it didn't take very long.
Wejustchose 70, andwedidthemall,practically
simultaneously, within one or two months. Also,
Ididn'thave to askpermissionfrom theDirector
ofthe Hospital. I didn't have to get permission
from the FDA orthe Government. There were no
ethical committees at the time, no guidelines,
laws orregimentations ....Idon'tremember-this
was in 1953 - whether Ieven asked thepatients.
Certainly there was no such thing as informed
consent at that time. I might have, but I don't
think so. Ijust ordered it. I might have told the
families ifthey visited ... We started in May and
by August we had written the paper... "
Increasingly,however, Iwasbecomingpersuaded
that psychotic illness was associated with a
localised brain abnormality and that a full
understanding ofthe condition required a proper
description both of the psychological function
that was disturbed and the location of this
abnormality within the brain. This, of course,
raises the old Cartesian chestnut but we are
beginning to see that a true account of
pathophysiology will avoid separating "mind"
from"body"byunderstandingthattheintegration
of all somatic, endocrine and neural functions
provides the subjective experience of
consciousness.14Iwasalsoconvincedthataproper
understanding of the mode of action of
antipsychoticdrugswouldleadtoimportantclues
about the nature of the illness itself.
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TABLE 2
Antipsychotic Drug Trials
Holywell Hospital 1975-1997
Novel Compounds
* propranolol (B adrenergic antagonist)
* ondansetron (5HT3 antagonist)
* M100907 (selective 5HT2A antagonist)
New atypicals
* remoxipride (selective D2 antagonist)
* quetiapine (5HT2 & D2 antagonist)
* sertindole (5HT2 & D2 antagonist)
* zotepine (5HT2 & D2 antagonist)
* ziprasidone (5HTIA agonist, 5HT2 & D2 antagonist)
Thegreatchallenge wastounderstandhow itwas
that antipsychotic drugs could have profound
effects on such afundamental human function as
thinking. So I embarked upon a review of the
effects of antipsychotic drugs on cognition and
found that the literature was in a real mess.' It
wasquitecleartherewasnogeneralagreementas
towhatwasmeantby"cognition"andinparticular
there was no consistency in the way trials were
beingcarriedout. Pharmacologistscontrolledthe
pharmacological aspects oftheirstudies butused
very simplistic measures of cognition and took
noaccountofneuropsychological subtleties such
as practice effects, while on the other hand
psychologists had sophisticated measures of
cognition but no proper control over or
understanding of the importance of controlling
fordose and the timing oftheir tests. It was quite
clear also that many of the studies in patients
were confounded by these and other variables
particularly the severity and nature ofthe illness
itself. There was also an apparentparadox in that
those drugs which improved thought disorder in
patientsgenerallyhadadverseeffectsoncognitive
function in normal healthy people.
Thus I embarked on a series of studies of the
effects of antipsychotics in healthy volunteers.
This was notwithout itshazards, because, as was
well known, healthy volunteers tolerated such
drugs poorly. In particular haloperidol caused
very unpleasant dysphoria and akathisia.16
Nevertheless, it was interesting that the dose at
which we found these effects emerging was very
similar to the "neuroleptic threshold" i.e. the
dose at which there were the first signs of
parkinsonian adverse effects in patients, i.e.
3.7 mg.'7 Among other things these studies led
me to realise that agreat deal of"dysphoria" was
being dismissed in psychiatric patients as part of
their illness rather than an adverse drug effect.
We found that healthy volunteers could in fact
tolerate most other antipsychotics, including
chlorpromazine as well as the newer atypicals,
quite well. We started with studies of saccadic
eyemovements,demonstratingthatpeaksaccadic
velocity was a good correlate of the sedative
properties ofthese drugs."8 19We then went on to
show that the antisaccade paradigm, which
recruited a "cognitive" component, was
paradoxically spared any impairment in spite of
clearevidenceofslowingofthe saccadicvelocity
and of substantial subjective sedation.20'2 This
"sparing" ofcognitive function was very similar
to that which had been previously observed by
MirskyandKornetskyinthe 1960susingasimple
digit symbol substitution test (DSST).22 We also
confirmed that memory was largely unaffected
by single doses of antipsychotics in healthy
volunteers.19' 23 More recently we have attempted
to replicate an animal model of the attention
deficit seen in schizophrenia, known as "latent
inhibition", and have, once again, found that this
isrelativelyunaffectedbyantipsychoticdrugs.24 25
Indeed, chlorpromazine actually improved
selectiveorfocusedattentionasmeasuredbythis
task. However a limitation of all these studies
was that we could not give the drugs chronically
forlong enough inhealthy volunteers to simulate
the situation of therapeutic dosing in patients.
Turning once again to animals we followed up
the theme of cognition by first establishing the
latent inhibition paradigm. This is supposed to
have "construct" validity in that it appears to
model a key deficit in schizophrenic thought
disturbance, namely the inability to ignore
extraneous and largely irrelevant stimuli. This is
done by having parallel groups of rats one of
which is "pre-exposed" to a flashing light while
the other is not. Following this training both
groups areexposedto anaversive stimuluswhich
hadpreviouslybeenlinkedwiththe"pre-exposed"
stimulus. The response to the aversive shock is
much less in the "pre-exposed" rat and the
difference is "latent" inhibition. We found that
both haloperidol and clozapine were effective in
this model 26 and also some novel compounds
such as antagonists of cholecystokinin,27 a
neuropepitide co-transmittedwithdopamine, but
©) The Ulster Medical Society, 2003.
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not selective dopamine D1 antagonists.28 Since
the latter had not been found to be clinically
effective either, these results strengthened the
relevance of the latent inhibition model.
But in order properly to understand the
neuropharmacologyofwhatwashappeningwhen
thebrainwasexposedtoantipsychoticcompounds
we decided to look at the effects of these
compoundsontheneurotransmitterreleaseinthe
core and shell ofthe nucleus accumbens using in
vivo microdialysis. The shell of the nucleus
accumbenslinkswiththemesolimbic areasofthe
brain while the core is closely linked with the
nigrostriatal areas. Thus the parkinsonian
extrapyramidal adverse effects ofantipsychotics
are linked with increased dopamine turnover in
the core of the nucleus accumbens while we
believe that the beneficial effects are associated
with a similar increased turnover in the shell.
Robert Moran, who set up this technique, was
thenabletodemonstrate aseparationbetweenthe
effects of haloperidol and clozapine (the first
"atypical" antipsychotic drug which is virtually
devoid of extrapyramidal side effects) on these
two areas ofthe nucleus accumbens.29'30
We have also established anotherway oflooking
at receptor pharmacology in rat brain through
radioligand binding in membrane homogenates
and by quantitative receptor autoradiography,
and Marie Cahir is currently looking at the
differential effects of typical and atypical
antipsychoticsonalanda2noradrenergicreceptor
subtypes.31'3233 Intheautoradiographytechnique,
after animals have been treated with different
antipsychotics, thebrainisremovedandsectioned
by microtome. The sections are incubated with a
radioligand (in this case tritiated prazosin, a
selective al adrenoceptor ligand), washed, dried
and then apposed to a radioactive sensitive film
for up to 6 weeks. The resulting images are
examined by a computer linked digital camera
system (Computer Assisted Image Analysis),
which produces colour-coded pictures revealing
the distribution and density of the receptors of
interest. Marie has shown that clozapine causes
an increase in a, receptors in a wide range of
cortical regions, which may reflect part of the
mechanismofits "atypical" action. Comparisons
with other atypical antipsychotics and with
chlorpromazine are ongoing. We will now be
starting to use this technique to examine the
effects ofmanipulating brain 5HTbytryptophan
depletion, on both serotonin, noradrenergic and
dopamine receptors in rat brain.
Finally incollaboration withDrStephenCooper,
we are currently developing functional
neuroimaging with Single Photo Emission
Computerised Tomography (SPECT), with the
hope ofalso being able to use Position Emission
Tomography (PET) scanning in Belfast in the
near future. We have been manipulating central
5HT using acute tryptophan depletion in both
healthy volunteers and schizophrenic patients,
and, using 99mTc-HMPAO SPECT, have
demonstrated that this procedure causes similar
decreases inregional cerebralbloodflow (rCBF)
in healthy volunteers as have been previously
demonstrated in depressed patients, but without
the concomitant subjective reaction of
depression.34 Thus afall ofserotonin seems to be
a necessary but insufficient explanation for
depression.
In schizophrenic patients, however, we found
increases rather than decreases in rCBF in those
sameprefrontal areasfollowing acutetryptophan
depletion.35 SincetheserCBFchangesprincipally
reflect glutamatergic function, these findings are
consistent with the theories of a glutamatergic
abnormality in this condition.
Furthermore, wehaverecentlygatheredevidence
that this fall in serotonin following acute
tryptophandepletionisassociatedwithimproved
ratherthanimpairedcognitiveperformanceusing
a"gambling"ordecisionmakingparadigm,which
is probably associated with increased activity in
the orbital frontal cortex or the ventro-medial
pre-frontal cortex. This is the area of the brain
which when damaged leads to undirected and
uninhibited behaviour, as in the classical case of
Phineas Gage and many others now referred. It
may also be impaired in psychiatric disorders
withcognitivedysfunction suchasschizophrenia
andeven,perhaps, inpsychopathicpersonalities.
Intriguingly, a recent study has found elevated
kynurenate (a metabolite of kynurenine and
ultimately of tryptophan) levels in one of these
prefrontalareas(Brodmanarea9)inschizophrenic
brain.36 Since kynurenate is aglutamate receptor
antagonist, tryptophan depletion might improve
cognitionbyreducingthelevelsofthismetabolite.
We are now combining our animal work with
these more recent human neuroimaging studies
and have set ourselves the task ofdefining "The
role of the pre-frontal serotonin system in
cognition", and this programme of research has
C The Ulster Medical Society, 2003.
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beenfundedaspartofarecently successfulbidto
establishaRecognisedResearchGroup(RRG)in
NeurosciencebytheR&DOfficeoftheNorthern
Ireland DHSSPS. We hope to demonstrate using
theanimalstudiesexactlywhathappensfollowing
acute tryptophan depletion not only to 5HT but
also to other neurotransmitter systems. We trust
that this will map on to the changes we see in
regionalcerebralbloodflowinhealthyvolunteers
after tryptophan depletion. We will then be in a
position to interpret the changes in regional
cerebral blood flow in schizophrenia.
Thus I have come full circle, backto tryptophan,
serotonin and psychosis: a road now more
travelled by!. It has been a fascinatingjourney. I
do not know what it all means and I am just as
puzzled as I was 30 years ago, but I still have the
conviction that this is one of the greatest
challenges we face in medical science and that
further exciting glimpses of the truth about the
brain and its most important functions lie ahead.
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